Filtered By:
Source: BMC Cancer
Drug: Gleevec
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia
Conclusions:
Our data suggest that STATIP1 may be a negative regulator of STAT3 and demonstrate its involvement in IM therapy resistance in CML.
Source: BMC Cancer - November 23, 2014 Category: Cancer & Oncology Authors: André MencalhaStephany CorrêaDaniela SallesBárbara Du RocherMarcelo SantiagoEliana Abdelhay Source Type: research
Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-beta
Conclusions:
The results suggest that imatinib mesylate may be useful in the treatment of MPNST patients and in vitro studies may help select cells that are sensitive to imatinib mesylate in vivo.
Source: BMC Cancer - May 4, 2013 Category: Cancer & Oncology Authors: Jun OhishiMikiko AokiKazuki NabeshimaJunji SuzumiyaTamotsu TakeuchiAkira OgoseMichiyuki HakozakiYuichi YamashitaHiroshi Iwasaki Source Type: research
